Impact of Antibiotic Gut Exposure on the Temporal Changes in Microbiome Diversity

التفاصيل البيبلوغرافية
العنوان: Impact of Antibiotic Gut Exposure on the Temporal Changes in Microbiome Diversity
المؤلفون: Burdet, Charles, Nguyen, Thu, Duval, Xavier, Ferreira, Stéphanie, Andremont, Antoine, Guedj, Jérémie, Mentré, France
المساهمون: Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Département d'épidémiologie, biostatistique et recherche clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Genoscreen [Lille, France], The randomized clinical trial was sponsored by Da Volterra (Paris) and funded in part by the European Union Seventh Framework Programme (FP7-HEALTH-2011-single-stage) under grant agreement number 282004, EvoTAR., DAV132-CL-1002 study group, European Project: 282004,EC:FP7:HEALTH,FP7-HEALTH-2011-single-stage,EVOTAR(2011)
المصدر: Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2019, 63 (10), pp.e00820-19. ⟨10.1128/AAC.00820-19⟩
بيانات النشر: HAL CCSD, 2019.
سنة النشر: 2019
مصطلحات موضوعية: metagenomics, nonlinear mixed effect modelling, dysbiosis, moxifloxacin, human activities, intestinal microbiome, [SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM], diversity
الوصف: International audience; Although the global deleterious impact of antibiotics on the intestinal microbiota is well known, temporal changes in microbial diversity during and after an antibiotic treatment are still poorly characterized. We used plasma and fecal samples collected frequently during treatment and up to one month after from 22 healthy volunteers assigned to a 5-day treatment by moxifloxacin (n = 14) or no intervention (n = 8). Moxifloxacin concentrations were measured in both plasma and feces, and bacterial diversity was determined in feces by 16S rRNA gene profiling and quantified using the Shannon index and number of operational taxonomic units (OTUs). Nonlinear mixed effect models were used to relate drug pharmacokinetics and bacterial diversity over time. Moxifloxacin reduced bacterial diversity in a concentration-dependent manner, with a median maximal loss of 27.5% of the Shannon index (minimum [min], 17.5; maximum [max], 27.7) and 47.4% of the number of OTUs (min, 30.4; max, 48.3). As a consequence of both the long fecal half-life of moxifloxacin and the susceptibility of the gut microbiota to moxifloxacin, bacterial diversity indices did not return to their pretreatment levels until days 16 and 21, respectively. Finally, the model characterized the effect of moxifloxacin on bacterial diversity biomarkers and provides a novel framework for analyzing antibiotic effects on the intestinal microbiome.
اللغة: English
تدمد: 0066-4804
1098-6596
URL الوصول: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ce35eee35c168bd954ba87a27ff95896
https://www.hal.inserm.fr/inserm-02362445
رقم الأكسشن: edsair.dedup.wf.001..ce35eee35c168bd954ba87a27ff95896
قاعدة البيانات: OpenAIRE